BioVacSafe Project BioVacSafe Project

Welcome to BioVacSafe Project

BioVacSafe - Biomarkers for enhanced vaccines immunosafety - is a 5 years project funded by Innovative Medicine initiative (IMI).

The goal of BioVacSafe is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. By  bringing  together for the first time three of Europe's  leading  vaccine  development  and manufacture companies as well as top experts from academic institutions and small and medium-sized enterprises (SMEs),  the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines. By sharing their expertise, the BioVacSafe partners have a unique opportunity to make progress in this important area.

Project Description

On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety.

BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.

The total budget of the project is 30.2 millions of Euros and it will last for five years.

Read more

Follow us:

facebook twitter linkedin

Project Objectives

The overall objective of the project is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market.

The three specific objectives of the project are:

• the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses;

• the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity;

• the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock.


BioVacSafe News BioVacSafe News

Early Career Research Prize in Vaccinology R&D 2018

The IUIS, together with Vaccines Europe will collect applications from members of IUIS, EFIS or any other European Immunology and/or Vaccinology Society and select a winner among them....

5th BioVacSafe Annual meeting

The 5th BioVacSafe Annual meeting will be held in Reykjavik from 8th to 10th June 2017. All partners and the members of the Scientific Advisory Board of the project will be invited to...

Events Events

19th – 23rd February 2017

Keystone Symposia: Viral Immunity – Mechanisms and Consequences will be held on 19th – 23rd February 2017 in Santa Fe, New Mexico, USA.

This meeting will foster new interactions and generate new ideas by assembling international experts in the areas of evolutionary perspectives on the host-virus relationship, innate immune detection and control of endogenous and exogenous viruses, memory cell control of viruses at mucosal surfaces, immunological consequences of prior viral exposure, and new approaches to vaccines and therapeutics. This comprehensive and inclusive approach should spur new thinking.

More information can be found here